Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 654.74

-0.5%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	7/21/2020 12:05:48 PM
	of 3557

RE: Dupi competitor, ABBV (upadacitinib) Second P3 AD data: prnewswire.com It appears that Upadacitinib is better JAK1 agent that PFE's Xeljanz, however after almost 12 months on US RA market... captured only 15% (Xeljanz continue to dominate...overall JAK use increased)! So, is side effect profile hardless, or PFE marketing machine so strong?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next